An overview of pharmacologic treatment of cognitive decline in the aged.
The most widely known substances that have been investigated for treating cognitive deterioration in the aged are cerebral vasodilators, Gerovital H3, psychostimulants, "nootropics," neuropeptides, and neurotransmitters. The rationale for the choice of specific agents has shifted as our conceptions regarding the origins of cognitive decline have changed; we now know that most cognitive deterioration occurs independently of arteriosclerotic vascular changes. Substances currently being investigated because of their effects on brain electrophysiology, on neurohumoral processes, or on central neurotransmitters show promise.
D000925:Anticoagulants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy*; D004088:Dihydroergotoxine / Q000627:therapeutic use; D006801:Humans; D006931:Hyperbaric Oxygenation; D008774:Methylphenidate / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010889:Piracetam / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000925:Anticoagulants; D010277:Parasympathomimetics; D010455:Peptides; D014665:Vasodilator Agents; D004088:Dihydroergotoxine; C004936:Gerovital H3; D008774:Methylphenidate; D011343:Procaine; D010889:Piracetam